Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

Diane M. Thiboutota Department of Dermatology, Pennsylvania State University College of Medicine, Hershey, PA, USAView further author information

Noah Craftb Department of Dermatology, Good Dermatology, Torrance, CA, USA;c Department of Dermatology, People Science, Venice, CA, USAView further author information

Robert Rissmannd Department of Dermatology, Centre for Human Drug Research, Leiden, The Netherlands;e Department of Biotherapeutics, Leiden Academic Center for Drug Research, Leiden University, Leiden, The NetherlandsView further author information

Ewa Gatlikf Novartis Institute for Biomedical Research, Basel, SwitzerlandView further author information

Malika Souquièresf Novartis Institute for Biomedical Research, Basel, Switzerland;g Priothera SAS, Saint-Louis, FranceView further author information

Julie Jonesh Biostatistical Sciences and Pharmacometrics, Novartis Pharma AG, Basel, SwitzerlandView further author information

Christian Loeschef Novartis Institute for Biomedical Research, Basel, SwitzerlandCorrespondence[email protected]

https://orcid.org/0000-0001-6505-0349 View further author information

show all

Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date